Literature DB >> 10683244

Cystic fibrosis transmembrane conductance regulator: the purified NBF1+R protein interacts with the purified NBF2 domain to form a stable NBF1+R/NBF2 complex while inducing a conformational change transmitted to the C-terminal region.

N T Lu1, P L Pedersen.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is known to function as a regulated chloride channel and, when genetically impaired, to cause the disease cystic fibrosis. The novel studies reported here were undertaken to gain greater molecular insight into possible interactions among CFTR's soluble domains, which include two nucleotide binding domains (NBF1 and NBF2) and a regulatory domain (R). The NBF1+R and NBF2 regions of CFTR were highly expressed in Escherichia coli, purified to near homogeneity under denaturing conditions, and refolded. Both refolded proteins bound TNP-ATP and TNP-ADP, which could be readily replaced with ATP. Four different approaches were then used to determine whether the NBF1+R and NBF2 proteins interact. First, the purified NBF2 protein was labeled near its C-terminus with a fluorescent probe, 7-diethyl amino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM). Addition of the unlabeled NBF1+R to the CPM-labeled NBF2 caused a red-shift in lambda(max) of the CPM fluorescence, consistent with a direct interaction between the two proteins. Second, when the NBF1+R protein, the NBF2 protein, and a mixture of the two proteins were folded separately and analyzed by molecular sieve chomatography, the mixture was found to elute prior to either NBF1+R or NBF2. Third, na-tive-PAGE gel studies revealed that the mixture of the NBF1+R and NBF2 domains migrated as a single band with an R(F) value between that of NBF1+R and NBF2. Fourth, trypsin digestion of a mixture of the NBF1+R and NBF2 proteins occurred at a slower rate than that for the individual proteins. Finally, studies were carried out to determine whether an NBF1+R/NBF2 interaction could be demonstrated after expressing one of the two proteins in soluble, native form, thus avoiding the inclusion body, denaturation, and renaturation approach. Specifically, the NBF1+R protein was overexpressed in E. coli in fusion with glutathione-S-transferase near a thrombin cleavage site. Following binding of the GST-(NBF1+R) fusion protein to a GST Sepharose affinity column, added NBF2 was shown to bind and then to coelute with NBF1+R upon addition of glutathione or thrombin. Collectively, these experiments demonstrate that CFTR's NBF1+R region and its NBF2 domain, after folding separately as distinct units, have a strong propensity to interact and that this interaction is stable in the absence of added nucleotides or exogenously induced phosphorylation. These findings, together with the additional observation that the NBF1+R/NBF2 interaction induces a change in the C-terminus of NBF2, which resides within the C-terminal region of CFTR, may have important implications not only for the function of CFTR per se, but its interaction with other proteins. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683244     DOI: 10.1006/abbi.1999.1656

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  12 in total

1.  Activation mechanisms for the cystic fibrosis transmembrane conductance regulator protein involve direct binding of cAMP.

Authors:  Malcolm M C Pereira; Jody Parker; Fiona L L Stratford; Margaret McPherson; Robert L Dormer
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

Review 2.  Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

3.  Biochemical dissection of the ATPase TraB, the VirB4 homologue of the Escherichia coli pKM101 conjugation machinery.

Authors:  Eric Durand; Clasien Oomen; Gabriel Waksman
Journal:  J Bacteriol       Date:  2010-02-19       Impact factor: 3.490

4.  Mutation of Walker-A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotide-binding domains.

Authors:  Allan C Powe; Layla Al-Nakkash; Min Li; Tzyh-Chang Hwang
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

5.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain.

Authors:  Valerie Chappe; Thomas Irvine; Jie Liao; Alexandra Evagelidis; John W Hanrahan
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

6.  Small-angle X-ray scattering study of the ATP modulation of the structural features of the nucleotide binding domains of the CFTR in solution.

Authors:  Lauretta Galeno; Elena Galfrè; Oscar Moran
Journal:  Eur Biophys J       Date:  2011-03-22       Impact factor: 1.733

7.  Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implications.

Authors:  Martina Gentzsch; Andrei Aleksandrov; Luba Aleksandrov; John R Riordan
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

8.  A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating.

Authors:  J Fu; H L Ji; A P Naren; K L Kirk
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

9.  Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain.

Authors:  L Daniel Howell; Roy Borchardt; Jolanta Kole; Andrew M Kaz; Christoph Randak; Jonathan A Cohn
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

10.  Cystic fibrosis transmembrane conductance regulator: the NBF1+R (nucleotide-binding fold 1 and regulatory domain) segment acting alone catalyses a Co2+/Mn2+/Mg2+-ATPase activity markedly inhibited by both Cd2+ and the transition-state analogue orthovanadate.

Authors:  Jean Philippe Annereau; Young Hee Ko; Peter L Pedersen
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.